NCT03833323View on ClinicalTrials.gov

Implantable System for Remodulin Post-Approval Study

WithdrawnOBSERVATIONAL

0

Timeline

Start Date

August 1, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions

Pulmonary Arterial Hypertension

Interventions

COMBINATION_PRODUCT

Implantable System for Remodulin (treprostinil)

All patients will be implanted with the Implantable System for Remodulin (treprostinil).

Sponsors

Collaborators (1)

United Therapeutics

All Listed Sponsors

collaborator

United Therapeutics

INDUSTRY

lead

Medtronic Cardiac Rhythm and Heart Failure

INDUSTRY